Altered Estrogen Receptor Signaling Pathway in BRCA2 ‐Deficient Estrogen Receptor‐Positive/ HER2 ‐Negative Breast Cancer

Key Points

• This research aims to characterize estrogen receptor signaling alterations in breast cancer with BRCA2 mutations.
• Detailed characterization of estrogen receptor signaling pathway alterations
• Focus on ER-positive/HER2-negative breast cancer
• Analysis of germline BRCA2 pathogenic variant (PV) impact
• Identified significant alterations in ER signaling due to BRCA2 PVs
• Provided insights for developing targeted therapeutic strategies
• Highlighted differences in treatment responses for this specific patient population